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1 Abstract 
 
An intense effort is made by pharmaceutical and academic research laboratories to identify and 
develop selective antagonists for each adenosine receptor (AR) subtype as potential clinical candidates 
for "soft" treatment of various diseases. Crystal structures of subtypes A2A and A1ARs offer exciting 
opportunities for structure-based drug design. In the first part of the present work, Maybridge 
HitFinderTM library of 14400 compounds was utilized to apply a combination of structure-based 
against the crystal structure of A2AAR and ligand-based methodologies. The docking poses were re-
scored by CHARMM energy minimization and calculation of the desolvation energy using Poisson-
Boltzmann equation electrostatics. Out of the eight selected and tested compounds, five were found 
positive hits (63% success). Although the project was initially focused on targeting the A2AAR, the 
identified antagonists exhibited low micromolar or micromolar affinity against A2A/A3 ARs or A3AR, 
respectively. Based on these results, 19 compounds characterized by novel chemotypes were 
purchased and tested. Sixteen of them were identified as AR antagonists with affinity towards 
combinations of the AR family isoforms (A2A/A3, A1/A3, A1/A2A/A3 and A3). The second part of this 
work involves the performance of hundreds of molecular dynamics (MD) simulations of complexes 
between the ARs and the total of 27 ligands to resolve the binding interactions of the active 
compounds, which were not achieved by docking calculations alone. This computational work allowed 
the prediction of stable and unstable complexes which agree with the experimental results of potent 
and inactive compounds respectively. Of particular interest is that the 2-amino-thiophene-3-
carboxamides, 3-acylamino-5-aryl-thiophene-2-carboxamides and carbonyloxycarboximidamide 
derivatives were found to be selective and possess a micromolar to low micromolar affinity for A3 
receptor. 
 
 
 
 
 
 
 
2 Introduction  
 
Adenosine receptors (ARs) belong to the family of G protein-coupled receptors (GPCRs) and are 
expressed in both the CNS and the periphery. The four AR subtypes (A1, A2A, A2B and A3) are 
responsible for a wide range of physiological processes by acting upon different signaling pathways. 
The A2A and A2B ARs increase 3΄,5΄-cyclic adenosine monophosphate (cAMP) levels by coupling to 
Gs, whereas the A1 and A3AR subtypes signal via Gi and decrease cAMP. 
1,2 Adenosine is involved in 
the regulation of several biological functions in different organs and tissues, including the CNS, the 
cardiovascular system and the airways; many pathophysiological states are associated with changes of 
adenosine levels. 3 For these reasons, selective agonists, antagonists and allosteric enhancers 4 provide 
promising clinical candidates. Indeed, therapeutic modulation of the adenosine system could offer the 
possibility of a "soft" treatment of different diseases, but due to the ubiquitous distribution of 
adenosine and its receptors, the challenge in ligand development depends on the specificity for the 
different receptor subtypes. A2AR antagonists have emerged as an attractive approach to treat 
Parkinson, sickle cell and infectious diseases, cancer, ischemia reperfusion injury, diabetic 
nephropathy, cognition and other CNS disorders. 5,6,7,8,9 A2BAR antagonists may be useful for the 
treatment of asthma, chronic obstructive pulmonary disease (COPD) and inflammation. 10,11,12 The 
A1AR is also an attractive pharmacological target. Its antagonists have been explored as kidney-
protective agents, cognitive enhancers, anti-asthmatic and CNS agents. 13 Finally, A3AR-selective 
antagonists are of interest for therapeutic applications in asthma, glaucoma, COPD etc. 14 
A breakthrough in the AR field was the publication of a crystal structure for the A2A subtype, 
which revealed the binding mode of the antagonist 4-[2-[7-amino-2-(2-furyl)-1,2,4-triazolo-[1,5-
a][1,3,5]triazin-5-ylamino]ethyl]phenol (ZM241385) (Figures S1, S2). 15,16 This enabled the use of 
remarkably successful structure-based approaches in ligand discovery providing high hit rates and 
novel ligands using A2AAR  
17,18,19,20,21,22,23,24,25,26 and homology models of A1 and A3AR derived 
therefrom. 27,28 In these studies, the ligand recognition occurs in the upper region of the transmembrane 
(TM) bundle, and the bound ligand is surrounded by TM3, 5, 6, and 7 and occasionally by TM2. The 
bound ligands are anchored inside the same binding cleft for all AR subtypes and can form up to two 
stabilizing hydrogen bonds with the side chain amide group of the N(6.55) 29,30 in TM6 (numbers in 
parentheses refer to the Ballesteros–Weinstein numbering31). The importance of interactions with 
N(6.55) was identified early in docking screenings. 18 N(6.55) and L(6.51) are key-to-recognition and 
highly conserved residues in all four AR subtypes and have been found to be crucial interaction 
partners for both agonists and antagonists in mutagenesis studies. 29 The ligands can occasionally form 
a tight hydrogen bond with the carboxylate group of E(5.30) in the extracellular loop 2 (EL2) in A1, 
A2A and A2BARs (see Figure S1). The recently published crystal structures of the A1AR bound to the 
selective covalent antagonist 8-cyclohexyl-3-(3-(4-fluorosulfonylbenzamido)propyl)-1-propylxanthine 
(DU172) 32 or 1-butyl-3-(3-hydroxypropyl)-8-(3-noradamantyl)xanthine (PSB36) 33 (Figure S2) can be 
utilized also for structure-based drug design and new insights into the selectivity of ligands against 
ARs.  
Although the docking campaigns applying convenient scoring functions were successful, 34 
molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) methods which account for ligand 
and the protein solvation before and after binding using an implicit solvation model 35 improved 
scoring significantly. 36,37,38,39 Since the AR-ligand complexes have considerable therapeutic impact, 
strategic longer MD simulation studies have been performed in order to test the effect of the starting 
conformation of the ligand, 40 the effect of protein flexibility on the binding conformation of the 
ligand, 41 the contribution of the lipid bilayer to the protein conformational space, 42 the 
conformational transition at long simulation times, 43,44 recognition pathways of the ligand 45 etc. The 
molecular binding interactions derived from structure-based virtual screening against ARs are often 
described better through all-atom MD simulations of the protein complexes. 19 
Here, we explored the in silico screening of 14400 compounds included by  Maybridge 
HitFinder library 46 against the X-ray structure of A2AR complexed with ZM241385 using a 
combination of structure-based and ligand-based approaches. The re-scoring of a subset of docking 
poses was performed with CHARMM-PBSA energy minimization to further account for desolvation 
energy. Eight compounds were selected and tested and five of them were identified as positive hits. 
Compounds 1 and 5 exerted low micromolar affinities against A2A/A3ARs (Table 1). Compound 2 
exhibited micromolar affinity against A3AR and a very weak affinity against A2AAR and compounds 6 
and 7 micromolar affinity against A3AR. Based on the structure of the three most promising 
compounds, 19 new compounds were purchased, of which 16 were found to be binders to ARs.  
Compounds 12, 14 and 23 exhibited affinity for A2A/A3, compounds 15, 21 and 26 for A1/A3,  
compounds 13, 16 and 17 for A1/A2A/A3, compound 27 for A1, and the eight compounds 9-11, 18, 20, 
22, 24, 25 were selective for A3. Molecular docking calculations and MD simulations of the 27 ligands 
against A1, A2A, A2B and A3ARs were employed in an attempt to provide clues about the compounds' 
binding interactions. Interestingly, the 27 tested ligands resulted in similar docking poses against A1, 
A2A, A2B or A3ARs. Thus, MD simulations of numerous complexes (which are possible only using 
supercomputers), have been applied to investigate further the basic binding interactions of the active 
compounds.  In particular, over two hundreds short (10 ns) MD simulations were performed with 
Desmond 47,48 using OPLS 2005 49,50,51 force field to relax ligand-receptor interactions. When the MD 
simulations resulted in a binding orientation similar to the docking pose (RMSDlig < 1.5 Å) the 
stability of the AR-ligands complexes was verified by performing longer (100 ns) MD simulations 
with Desmond 47,48 using OPLS 2005 49,50,51  force field and with Amber 52 using ff14SB 53 to model all 
protein and ligand interactions. A work flow of the computational methods used is presented in 
Scheme 1. The eight A3AR-selective compounds provide novel chemotypes which may find use in 
various human pathologies.  
 
3 Materials and Methods 
 
Molecular docking and scoring calculations of the Maybridge HitFinder 
library 
 
Ligand Preparation 
Prior to the docking calculations, the Maybridge HitFinder library 46 was prepared using the LigPrep 
workflow as implemented on Maestro 10.3 (Schrödinger Release 2016-3: LigPrep, Schrödinger, LLC, 
New York, NY, 2016). The initial 14400 structures gave 19229 tautomers. Those tautomers were 
subjected to conformational analysis using OMEGA software (OpenEye Inc) 54,55 resulting in 1655368 
conformers which were used for virtual screening. 
 
Virtual Screening 
The molecular docking calculations were carried out using the 2.6 Å resolution crystal structure of the 
human A2AAR in complex with the antagonist ZM241385 (PDB ID 3EML). 
15 This virtual screening 
project started just before any other X-ray structure was published. 16,21,56,57 Among the crystal 
structures of A2AAR-antagonist complexes released after 3EML, PBD ID 4EIY 
57 contained also co-
crystallized ZM241385 possessed the highest  1.8 Å resolution. Both the desolvation energy for 
inserting a compound into the receptor and its attractive interactions with the orthosteric binding area 
of A2AAR were used as contributions to energy during hit selection. In this context, the shape and 
coordinates of the critical amino acid side chains participating to interactions with the ligands inside 
the binding site, do not differ essentially between 3EML and the other newer released structures, for 
example 3PWH (3.3 Å), or the highest in resolution 4EIY. Figure S3 shows the superposition of 
3EML, 4EIY and 3PWH. The highest resolution receptor structure 4EIY is nearly identical to the 
original 2.6 Å resolution crystal structure 3EML with an all-atom RMSD of 0.45 Å to 81% of A2AAR. 
Recently, it was reported that a virtual screening performed against A2AAR using two different X-ray 
structures (PDB ID 4EIY, 3PWH) resulted in 11 ligands with affinity to A2AAR. 
26 Five were 
identified from docking using Glide and structure 4EIY and six were identified by the Glide docking 
based on structure 3PWH, i.e., the virtual screening based on the two crystal structures produced 
different hits. Nevertheless, we did not test a second virtual screening using 4EIY or other protein co-
crystallized  structure of AR with a ligand. 
Using 3EML structure, the complex was prepared for the calculations by removing all non-
protein atoms and the intracellular T4-lysozyme insertion. The most favoured protonation states of 
ionizable residues (D, E, R, K and H) at pH 7 were assigned using Maestro. 58 The protonation states 
of the histidines in the binding region were set according to literature data in order to contribute to the 
stabilization of complexes. His7.43 was protonated at epsilon position to form H-bonds with the 
ligands (see for example Figures 4c, 6b). His6.52 was protonated at the epsilon position so as to form 
possible interactions with waters according to the literature.  His6.66, at the top of the ligand binding 
site, was doubly protonated to form a salt-bridge with Glu5.30 in A2A and A1AR subtypes; in A3AR it 
was protonated at the delta position to avoid repulsive interactions since A3AR has a Val instead of 
Glu5.30. The N- and C-termini of the protein were capped by acetyl and methylamino groups, 
respectively, after applying the protein preparation module of Maestro. 40,58 All hydrogens atoms of the 
protein-ZM241385 complex were minimized with the AMBER* force field by means of 
Maestro/Macromodel 9.6 using a distance-dependent dielectric constant of 4.0. The MM 
minimizations were performed with a conjugate gradient (CG) method and a root mean square of the 
energy gradient (threshold) value of 0.0001 kJ Å-1 mol-1 was used as the convergence criterion. The 
apo-protein and ZM241385 structures were saved separately and used for the subsequent docking 
calculations. Molecular docking was performed with GOLD 5.2. 59,60,61  The ligand binding site was 
defined within 15 Å of the native ligand in the receptor structure. Comparison of the best docking 
poses obtained with GoldScore, 60 ChemScore 62 and ChemPLP 63 afforded an RMSD of of 1.1 Å, 4 Å 
and 0.80 Å respectively for ZM241385, relative to the X-ray coordinates 15. Therefore, further docking 
calculations were performed using the ChemPLP 63 scoring function. The energy minimized ligands 
structures were submitted to ten genetic algorithm runs which is the default value used by the GOLD 
program. The “allow early termination” command was activated (which terminates searching for a 
ligand if the top three solutions have an RMSD difference in their coordinates smaller than 1.5 Å) and 
the docking poses were clustered using an RMSD difference criterion of 1.5 Å. All other parameters 
were set to their default values. In total, 48230 clusters and representative docking poses (Scheme 1) 
were selected. 
 
3D Similarity Calculations 
The ligand-based virtual screening tool Rapid Overlay of Chemical Structures (ROCS) 64 was used to 
predict structures that were similar to ZM241385 (molecular query). In brief, the docking poses of 
each compound were superimposed and scored on the basis of their overlap with the query in terms of 
shape (ShapeTanimoto) and functional groups (ColorTanimoto). All of the 3D similarity calculations 
were ranked according to the TanimotoCombo metric, which is the sum of the ShapeTanimoto and 
ColorTanimoto scores and thus ranges from 0 to 2. The top 6000 solutions (TanimotoCombo 
coefficient > 0.65) were selected for re-scoring using the MM-PBSA method as follows. 
 
CHARMM-PBSA re-scoring 
Energy minimization. Complexes of 6000 docking poses with A2AR were subjected to MM-PBSA 
calculations using the CHARMM program 65,66 after applying a software for fragment-based molecular 
docking and protein structure preparation created by the A. Caflisch group. 67 All ligand-protein 
complexes were minimized with the CHARMM27 force field by the CG algorithm to a threshold value 
of 0.001 kcal mol-1 Å-1. During minimization, the electrostatic energy term was screened by a distance-
dependent dielectric of 4r to prevent artificial deviations due to vacuum effects and the default 
nonbonding cutoff of 14 Å was used. Protein atoms were kept fixed. The minimized structures were 
used for evaluating the van der Waals and Coulomb energy, and solvation energies using finite-
difference Poisson calculations. 
Binding Energy Calculations. The van der Waals and electrostatic interaction energies were 
calculated by subtracting the values of the isolated components from the energy of the complex. The 
van der Waals energy was calculated with CHARMM27 force field using the default cutoff of 14 Å. 
The electrostatic energy is the sum of the Coulomb energy in vacuum and the solvation energy. The 
electrostatic energy was calculated with CHARMM 66 using infinite cutoff and neglecting interactions 
between pairs of atoms separated by one or two covalent bonds. The electrostatic solvation energy was 
calculated by the finite-difference Poisson approach 68 using the PBEQ (Poisson-Boltzmann equation) 
module 69 in CHARMM and a focusing procedure with a final grid spacing of 0.3 Å. The size of the 
initial grid was determined by considering a layer of at least 20 Å around the solute. The dielectric 
discontinuity was delimited by the molecular surface spanned by a rolling probe of 1.4 Å. The ionic 
strength was set to zero, and the temperature to 300 K. Two finite-difference Poisson calculations were 
performed for each of the three systems (ligand, protein, and ligand-protein complex). The solvation 
energy is the difference between the values from calculations between ligand-protein complex and 
ligand and protein alone. The exterior dielectric constant was set to 78.5 and 1.0 in the first and second 
calculation, respectively, while the solute dielectric constant was set to 1.0, which is consistent with 
the value used for the parameterization of the charges and the membrane-protein environment. Eight 
compounds were selected for testing based on their synthetic feasibility and structural availability (see 
Table S1) of which five were identified to be positive hits. 
 
Calculations of the tested ligand - AR complexes 
 
Models for A1, A2A, A3 and A2BARs. For calculations of the complexes between ligands and A2AAR 
or A1AR, the X-ray structure of hA2AAR (PDB ID 3EML 
15) and the recent X-ray structure hA1AR 
(PDB ID 5UEN 32) were respectively used. Since there are no crystal structures available for A2B and 
A3ARs , their  homology models developed by Katritch and Abagyan 
70 were used for the relevant 
calculations. Additionally, the homology models of of A2B and A3ARs available from the Adenosiland 
server of Moro were used. 71 Structures in Adenosiland of Moro 71 included all residues and did not 
need any additions. The homology models were built using the crystal structure of the hA2AAR (PDB 
ID 3EML 15) as a template. These receptor structures were used directly for the docking calculations, 
without the addition of any missing residues. In order to obtain suitable structures of AR-ligand 
complexes for performing MD simulations, missing portions of the A1, A2A, A2B and A3AR structures 
were generated with the software MODELLER. 72,73 The missing residues in the crystal structure of 
A2AAR (PDB ID 3EML 
15) i.e., M1-I3 (N-terminus), P149−H155 (extracellular loop 2, EL2), and 
K209-A221 (intracellular loop 3, IL3) were added. The final structure lacks the C-terminus and 
contains only residues 1 to 310. A similar procedure was followed for A1AR. It should be noted that 
the Katritch-Abagyan 70 structures were optimized by taking into account the binding energies from 
molecular docking calculations and the experimental selectivity of ligands for the four AR 
subtypes.70,71  In Katritch-Abagyan 70 structures of the A3 and A2BARs the portion that corresponds to 
the EL2 between positions L4.62 and C5.27 is missing. 72,73 As it has been reported, EL2 may 
orchestrate a network of interactions that can stabilize the inactive conformation of the receptor and/or 
kinetically control the receptor-ligand recognition. 74,75 A2B subtype is characterized by the longest 
EL2, while A3 subtype by the shortest. 
76 Despite the high degree of structural diversity with respect to 
EL2 in family A GPCRs, there is one feature that is conserved in the vast majority of them, that is the 
disulfide bond between EL2 and C3.25 at the top of TM3. This disulfide bond effectively tethers EL2 
on the top of the TM helical bundle and imposes a very important conformational constraint upon EL2. 
Some GPCRs have additional disulfide bonds between different ELs such as between EL2-EL1 found 
in all A2A subtype receptors. 
77 Furthermore, the A2AAR subtype possesses an additional intra-loop 
disulfide bond, within EL3, in common with melanocortin receptors and human histamine receptor 1. 
These “additional” disulfide bonds contribute in reducing the flexibility of ELs and, as a consequence, 
they peculiarly sculpt the topography of the extracellular portion of the receptor proximately to the 
orthosteric binding cleft.  
It has been shown that the A1AR binding area is broader compared to that of A2AR, including a 
secondary binding region next to the common orthosteric one. The compact structure of the TM bundle 
in A2AAR is consistent with its unique disulphide bond (C74-C146) through which the beginning of 
TM3 is tightly connected to the end of EL2 allowing shifts in TM1, 2, and 3 as suggested in ref. 32 and 
in this work. Both A1 and A3AR lack this disulphide bond. According to ref. 32, TM7 tilts towards 
TM6, possibly as a result of a shorter EL3 in A1AR owing to the deletion of one amino acid; EL3 is 
also one amino acid shorter in A3AR compared to A2AAR. These differences in tethering of the ELs 
result in the different shapes of the binding sites. 
Almost all AR subtypes contain an E(5.30) residue, except A3AR which contains a V(5.30). This 
glutamic acid residue may play an important role in high affinity ligand binding through the formation 
of a hydrogen bond, for example, with an unsubstituted exocyclic amine. Having a valine substituting 
this position, A3AR lacks this interaction and therefore allows bulky amine substitutions or 
neighbouring lipophilic fragments to protrude towards the extracellular opening of the pocket. Katritch 
and Abagyan reported 70 that some valine rotamers can also partially block this opening, thus using an 
optimized conformational model of the receptor may be required for specific investigation of ligand 
binding against A3AR.  
Docking calculations. The structures of ligands 1-27 (Table 1) were built by means of Maestro 
8.5 and were subsequently minimized by means of Macromodel 9.6 and the MMFF94 force field 78,79 
using the CG method and a distance-dependent dielectric constant of 4.0 until a convergence value of 
0.0001 kJ Å-1 mol-1 was reached. The 27 ligands depicted in Table 1 were subjected to docking 
calculations with Gold5.2 59,60,61 using both the GoldScore 60 and ChemPLP 63 scoring functions. 
Regarding the complexes with A2AAR and A1AR the PDB IDs 3EML 
15 and 5UEN 32 were 
respectively used. The homology models of both Moro and Katritch-Abagyan were used for the A3 and 
A2BARs. The binding site for the docking calculations of the 27 ligands was defined using the 
coordinates of ZM241385 in A2AAR (PDB ID 3EML 
15) which was selected as reference ligand. All 
protein atoms within 10.0 Å of the selected ligand were used in the binding site definition. The ligands 
were submitted to 10 genetic algorithm runs. Docking poses for each ligand were visualized using the 
UCSF Chimera package. 80 The tested molecules 1-27 resulted in similar docking poses against A1, 
A2A, A2B or A3ARs independently of the protein model used and scoring function. Thus, MD 
simulations were performed to investigate the basic binding mode features for compounds exhibiting 
affinity to the above mentioned receptors.  
MD simulations. MD simulations for 10 ns were performed for ligands 1-27 (Table 1) 
complexed at A2A, A1, A3 and A2BARs, and embedded in hydrated POPE bilayers. 
42 The docking 
poses of ligands 1-27 inside the othrosteric binding site of A2A, A1, A3 and A2BARs were used as 
starting structures. The ligands are allowed to relax close atom contacts and adopted a more favorable 
binding orientation. 43 The choice between DMPC, POPE and POPC as the model membrane bilayer 
for the MD simulations, was based on test calculations. 70 ns MD simulations for ZM241385-A2A 
complex in the different lipid bilayers were applied. POPE bilayers resulted in the smallest 
displacement (RMSD) from the crystallographic coordinates (see Figures S4, S5). For the comparison 
to be reliable, the average area per lipid head group in each lipid model was measured for each bilayer 
system at the end of the MD trajectory and was compared to the experimental values. The area per 
lipid was measured based on a combination of the two-dimensional Voronoi tessellation and the Monte 
Carlo integration method. 81 The time courses (Figure S6) and measures (Table S2) obtained, provided 
consistent values with the experimental ones for pure lipid bilayers suggesting that the membranes 
were properly equilibrated. More than two hundred MD simulations, performed in duplicate for each 
complex, were performed in supercomputers using Desmond 47,48 with OPLS 2005 force field. The 
duration of each MD simulation was 10 ns and the RMSD of the ligand inside the binding site was 
measured with respect to its docking pose coordinates (see RMSDlig. values in Table S3). We observed 
complexes where the ligand escapes from the orthosteric binding area and the RMSDlig. value was in 
most of the cases ≥ 4 Ǻ at the end of the simulation, and complexes in which the ligand retained a 
binding orientation similar to the starting docking pose where the RMSDlig. value was 2-3 Ǻ. In the 
latter cases, the stability of the complex was further verified by extending the simulation time to 100 ns 
(see Table S3). 49,50,51 The stability of the ligand-AR complexes was verified for ligands 1, 2, 5, 12, 13, 
14, 16, 17, 23 to A2AAR, ligands 13, 15, 16, 17, 21, 26, 27 to A1AR and ligands 1, 2, 5, 6, 7, 9-18, 20-
25, 27 to A3AR. Figures 1-7 depict the binding orientations of representative complexes. To further 
test the stability of these complexes, 100 ns MD simulations were performed on the representative 
complexes 1-A2A, 1-A3, 5-A2A, 5-A3, 13-A2A, 11-A3, 17-A2A, 17-A1 and 17-A3 using Amber with 
ff14SB force field for the ligand-protein complex 53 and lipid14 parameters for the lipid (Scheme 1). 82  
The procedure applied for the MD simulations was the following. The N- and C-termini of the 
protein model systems were capped by acetyl and methylamino groups, respectively, after applying the 
protein preparation module of Maestro. The AR complex was embedded in a POPE lipid bilayer 
extending 15 Å beyond the solute. The ligand-receptor complex was placed into the membrane 
according to the orientation with respect to the membrane plane (x-y plane) suggested by the 
"Orientations of Proteins in Membranes (OPM)" server. 83 Complex and lipid systems were solvated 
using the TIP3P 84 water model. Na+ and Cl- ions were placed in the aqueous phase to neutralize the 
systems and reach the experimental salt concentration of 0.150 M NaCl. The total number of atoms in 
each system was approximately 81770. Membrane generation and system solvation were conducted 
with the "System Builder" utility of Desmond. 47,48 The OPLS 2005 force field 49,50,51 was used to 
model all protein-ligand interactions and lipids. The particle mesh Ewald method (PME) 85,86 was 
employed to calculate the long-range electrostatic interactions with a grid spacing of 0.8 Å. Van der 
Waals and short-range electrostatic interactions were smoothly truncated at 9.0 Å. The Nosé-Hoover 
thermostat 87 was utilized to maintain a constant temperature in all simulations, and the Martyna-
Tobias-Klein method 87 was used to control the pressure. Periodic boundary conditions were applied 
and the dimensions of the simulation box were (80×95×110) Ǻ3. The equations of motion were 
integrated using the multistep RESPA integrator 88 with an inner time step of 2 fs for bonded 
interactions and non-bonded interactions within a cutoff of 9 Å. An outer time step of 6.0 fs was used 
for non-bonded interactions beyond the cut-off. Each system was equilibrated using a modification of 
the default protocol provided in Desmond. The modification of the protocol consists of a series of 
restrained minimizations and MD simulations designed to relax the system, while not deviating 
substantially from the initial coordinates. First, two rounds of steepest descent minimization were 
performed using a maximum of 2000 steps and harmonic restraints of 50 kcal mol Å-2 applied on all 
solute atoms, followed by 10000 steps of minimization without restraints. The first simulation was run 
for 200 ps at a temperature of 10 K in the NVT (constant number of particles, volume, and 
temperature) ensemble with solute heavy atoms restrained by a force constant of 50 kcal mol Å-2. The 
temperature was then raised during a 200 ps MD simulation to 310 K in the NVT ensemble with the 
force constant retained. The temperature of 310 K was used in MD simulations in order to ensure that 
the membrane state is above the main phase transition temperature of 298 K observed for POPE 
bilayers. 89 The heating was then followed by equilibration simulations. First, two 1 ns stages of NPT 
equilibration (constant number of particles, pressure, and temperature) were performed. In the first 1 
ns stage, the heavy atoms of the system were restrained by applying a force constant of 10 kcal mol Å-2 
for the harmonic constraints and in the second 1 ns stage the heavy atoms of the protein-ligand 
complex were restrained by applying a force constant of 2 kcal mol Å-2 to equilibrate solvent and 
lipids. This  equilibration protocol was followed by 10 ns simulation without restraints in POPE. For 
stable complexes, the NPT simulation time was extended to a 100 ns.  
Regarding  the calculations using Amber software, after the protein ligand-complex was inserted 
to the POPE bilayer according to the procedure reported above, 83 the systems were processed by the 
LEaP module in AmberTools14, 52 where Amber ff14SB force field parameters 53 were applied to the 
protein and lipid14 82 to the lipids and TIP3P 84 to the water molecules. As for the ligands, the atomic 
charges were calculated using the R.E.D. Server development 90 along with PARM10 parameters. 91 
NPT simulations were performed on the protein-membrane systems using the GPU implementation of 
the AMBER 12 code, 52 after a short energy minimization and equilibration in the NVT ensemble. The 
equilibration was followed by a 100 ns NPT simulation without restraints. 
All the MD simulations were run on ARIS and CyTERA Supercomputing Systems or in 
workstations using the GPU implementation of the MD simulations codes. 
The X-ray structures of A2A-ZM241385 and A1AR-DU172 complexes and the relevant Katritch-
Abagyan 70 or Moro A2A and A1AR structures when subjected to MD simulations for 10 ns in POPE 
bilayers resulted to similar structures as demonstrated by RMSDs  2 Å for Cα-carbons. Similar 
structures were acquired after the MD simulations for representative A3AR-ligand complexes using 
either the A1 or A2AAR experimental structure for building the homology model. The A3AR binding 
area was found to be broader than that of A2AAR as mentioned in ref. 70 due to the absence of the 
disulphide bond C74-C146 and tethering of TM3 with EL2. 
 
2D Similarity Calculations 
 
Similarity calculations for ligands were carried out using the Canvas program by Schrödinger. 92 In 
order to investigate the novelty of the discovered hits, we calculated the maximum pairwise Tanimoto 
similarity of each hit in respect to the thousands of known AR ligands in the ChEMBL22 database 
using the extended chemical fingerprints for four atoms (ECFP4). 93,94 (see Table S4). The Tanimoto 
coefficient (Tc) quantifies the two-dimensional chemical similarity between two molecules by 
adopting a value between 0 and 1.  
 
Pharmacological Characterization 
 
Radioligand Binding Studies at human A1, A2A and A3ARs 
All pharmacological methods followed the procedures as described in the litarature. 95 In brief, 
membranes for radioligand binding were prepared from CHO cells stably transfected with hAR 
subtypes in a two-step procedure. In the first step, cell fragments and nuclei were removed at 1000 x g 
and then the crude membrane fraction was sedimented from the supernatant at 100000 x g. The 
membrane pellet was resuspended in the buffer used for the respective binding experiments and it was 
frozen in liquid nitrogen and stored at -80 ºC. For radioligand binding at the hA1AR, 1 nM [
3H]CCPA 
was used, for hA2AAR 10 nM [
3H]NECA and for hA3AR 1 nM [
3H]HEMADO. Non specific binding 
of [3H]CCPA was determined in the presence of 1 mM theophylline and in the case of [3H]NECA and 
[3H]HEMADO 100 μM R-PIA was used. 96 Ki values from competition experiments were calculated 
using the program Prism (GraphPad Software, La Jolla, CA, U.S.A.) assuming competitive interaction 
with a single binding site. The curve fitting results (see Figure 8) showed R2 values ≥ 0.99 for all 
compounds and receptors, indicating that the used one-site competition model assuming a Hill slope of 
n=1 was appropriate. The affinity of the ligands is depicted in Table 1. 
 
Adenylyl cyclase activity 
The potency of antagonists at the hA2BAR was determined by adenylyl cyclase experiments. The 
procedure was carried out as described previously with minor modifications. 95,97 Membranes were 
prepared from CHO cells stably transfected with hA2BAR using only one high speed centrifugation of 
the homogenate. The resulting crude membrane pellet was resuspended in 50 mM Tris/HCl, pH 7.4 
and immediately used for the cyclase assay. Membranes were incubated with about 150000 cpm of [a-
32P]ATP for 20 min in the incubation mixture as described without using EDTA and NaCl. 97 None of 
the compounds showed measurable interaction with A2BAR, as the IC50-values for concentration-
dependent inhibition of NECA-stimulated adenylyl cyclase were all > 30 µM. 
 
 
 
 
4 Results and Discussion 
 
Molecular docking, scoring and selection of compounds for testing 
 
Molecular docking calculations were applied to 14400 compounds (included in the HitFinder 
collection of Maybridge) against an A2AAR crystal structure (PDB ID 3EML) 
15 after generating 200 
conformations for each ligand using the program OMEGA (see Scheme 1 and Materials and Methods 
Section). 55 The docking calculations were performed on the resulting library (1655368 conformers) 
with GOLD5.2 59,60,61 and ChemPLP 63 was used as the scoring function to produce 48230 clusters of 
docking poses. These were overlaid onto the crystallographic ZM241385 conformation adopted inside 
the crystal structure of A2AAR 
15 using ROCS 98 which relies on the detection of molecules with 3D 
properties similar to those of the reference compound. The top 6000 conformers were re-scored by a 
CHARMM-PBSA minimization (see Table S1).  This last filtering was very important since the 
docking poses from the previous step had similar polar and vdW contacts. The top 60 docking poses 
from 60 different compounds were selected and eight compounds were purchased based on the 
structural versatility and synthetic feasibility. From the eight compounds tested (Scheme 1) five were 
found to be positive hits (62.5% success) showing mixed antagonistic activity against ARs with 
affinities ≤ 20-30 μΜ. Remarkably, none of these eight positive hits was among the 60 after just 
applying: a) docking with GOLD and scoring with ChemPLP, and b) filtering with ROCS using 
scoring based on Tc (see Table S5). Thus, the CHARMM-PBSA re-scoring step which accounts for the 
desolvation energy needed in order the ligand to reach the receptor binding area was significant for 
ligands filtering. Several approaches were also applied in previous virtual screening attempts for 
improving ligand enrichment. These works include a combination of scoring tools for filtering. In the 
first campaigns, an optimized docking protocol was applied 18 or a docking and scoring using DOCK 
program which also accounted for the desolvation penalty.17 Other groups applied also a 
docking/scoring using DOCK which accounted for the desolvation penalty 19 27 or applied GlideSP/XP 
and other tools like induced fit docking.22  In a recent effort after docking and scoring with Glide/SP, 
REOS/Knime filtering was applied and then MM-GBSA calculations were performed which account 
for the desolvation penalty; in this particular effort after testing 79 compounds only two were found to 
meet the criterion of approximately 50 % radioligand displacement at a concentration of 10 μΜ. 25 
ARs are not easy targets for achieving selectivity since they have broad and similar orthosteric 
binding sites. Thus, it is not a surprise the fact that a research targeting a particular AR subtype can 
lead to antagonists of another AR subtype. A characteristic example that illustrate this point, is the 
virtual screening campaign starting with four separate homology models of the human A1AR and 
docking of 2.2 million compounds to all four models. Thirty-nine (39) hits were selected and tested for 
their binding in three AR subtypes. They were found to bind to two or three AR subtypes resulting in 
21% A1, 38% A2A and 36% A3AR successful antagonist hits. 
27    
Nineteen (19) molecules were selected from the e-molecules search engine, based on their 
similarity to the structures of compounds 1, 2 and 5, which are the most accessible with regards to their 
chemical synthesis. In particular, compounds 9-13 were selected based on the structure of 1. 
Compounds 1, 9-13 contain an amino group at 2-thiophene position and an amido (CONHR) group at 
3-thiophene position. Compared to 1, and 9-13 compounds 14-18, 26, 27 were selected to contain  the 
CONH2 group at 2-thiophene position and the NHCOR' group at 3-thiophene position. Compound 19 
was selected to resemble structure 2 and 20-25 were selected based on the structure of 5. The results 
from testing of compounds 9-27 are depicted in Table 1 and show that 23 compounds out of the 27 
compounds are binders of various combinations of ARs with weak to potent antagonistic activity. Thus 
their Ki values ranged from 61 μΜ to submicromolar values. Overall, out of all 27 compounds included 
in Table 1 only four compounds lack affinity against any ARs (3, 4, 8, 19). The model used to fit the 
binding data and determine Ki values confirms competitive interaction with the receptors (see Figure 
8).99 
 
Compounds classification, binding assays results and novelty 
 
Compounds classification and affinity results 
The 27 compounds can be categorized according to their structural similarity characteristics in five 
classes (A-E), or in four classes according to receptor selectivity, i.e. ligands with affinity only against 
A3, against A2A/A3, against A1/A3, and against A1/A2A/A3 ARs. 
Class A: Class A includes 2-amino-thiophene-3-carboxamides 9-11 and 2-amino-5-phenyl-3-
thiophenecarbohydrazides 1, 12 and 13. Derivatives 9, 10 and 11 exhibited binding only to A3AR, with 
corresponding Ki values being 16.5, 14.8 μΜ, while 9 possess a weak affinity with Ki = 37.1 μΜ. The 
addition of a condensed cyclopentane or cyclohexane ring to the thiophene ring in 9, resulted in 10 and 
11 respectively, which exhibited ~ two-fold increased affinity (Table 1). When a 3-phenyl group was 
added to the thiophene ring, the resulting 2-amino-5-phenyl-3-thiophenecarbohydrazide derivatives 12 
and 1 exhibited affinity for A2A/A3AR with Ki values 3.93, 5.77 μΜ and 2.67, 3.10 μM respectively, or 
in the case of 13 against A1/A2A/A3AR (Ki values 15.2, 4.59, 5.16 μΜ). 
Class B: This class includes the 3-acylamino-thiophene-2-carboxamides 15, 26, 27 and the 5-
aryl-3-acylamino-thiophene-2-carboxamides 16-18 (aryl group is 3-thiophenyl, phenyl and p-
chlorophenyl respectively). Compound 14, being a 3-amino-thiophene-2-carboxamide derivative is 
also included in class B. Derivatives 16 and 17 bind to A1/A2A/A3AR (Ki values 1.18, 4.69, 1.65 μΜ 
and 1.09, 7.29, 0.918 μΜ respectively). Ιn 18 the 3-acylamino group is bulky and thus selectivity for 
A3AR was obtained (Ki = 1.55 μΜ), while 15 which lacks 5-aryl substituent devoids of A2AAR 
affinity. In particular 15 exhibited an A1/A3AR affinity (Ki values 7.48 and 5.39 μΜ), along with 26 (Ki 
values 7.33 and 27.4 μΜ). Compound 27 demonstrated affinity against A1 (Ki = 18 μΜ). In 14, the 
lipophilic acyl substituent is not linked to the 3-amino group leading to moderate A3AR affinity (Ki = 
19.7 μΜ) and weak A2A affinity (Ki = 31.7 μΜ), while the A1 affinity was abolished. 
Class C: This class includes methanimidothioate derivatives 2 and 19. Compound 19 lacks any 
affinity compared to derivative 2 which exhibited moderate A3AR affinity and a very weak A2AAR 
affinity (Ki values were 16.6 and 61.3 μΜ respectively). It seems that the substitution pattern is 
important for the affinity profile and this may trigger additional SAR studies in the future.  
Class D: Members of this class are compounds 3, 5, 20-25 which bear a 
carbonyloxycarboximidamide segment, and 4 which bears a ureacarboximidamide. In most of the 
Class D compounds the carbonyl group of this fragment is connected to a 3-phenyl-isoxazole (a biaryl 
group) at 4-position and the carboximidamide carbon is connected to an aromatic moiety, like a 
substituted phenyl, pyridinyl or 4-thiazolyl group. The carbonyloxycarboximidamide derivatives 20, 
22, 24 and 25 exhibited selective binding to A3AR (from moderate to low micromolar affinity with Ki 
values being 30.9, 4.49, 4.16 and 0.899 μΜ). Compared to 20 the presence of the bulky iodine in the 
phenyl group in 21 led to increase in A1/A3AR affinity (Ki values 6.90 μM / 4.13 μΜ in 21 compared 
to > 100 μΜ / 30.0 μΜ respectively in 20). Considering the structures of 5, 24, and 25 possessing 2-
methyl-1,3-thiazole linked to the carboximidamide carbon, the presence of a chloro substituent in the 
phenyl ring of 3-phenyl-isoxazole favors A3AR selectivity. The measured Ki values of 5 were 21.8 / 
9.45 μM for A2A/A3AR while 24 and 25 exhibited A3AR selectivity with Ki values of 4.16 and 0.899 
μΜ respectively. The transposition of the pyridinyl nitrogen from 3-position in 22 to 4-position in 23 
effects a small decrease to A3AR affinity, with  a change of Ki value from 4.49 to 5.15 μΜ, and the 
appearance of a weak A2AR affinity with Ki value of 30 μΜ. In the inactive derivative 3, the monoaryl 
and biaryl groups are connected to the carbonyloxycarboximidamide fragment in a transposed way. In 
the inactive aminomethylidenehydrazine-1-carboxamide analogue 4 the carboxy group has been 
replaced by an urea fragment.  
Class E:  This class contains molecules than cannot be classified in any of the above classes. 
The pyrimidin-4-amine 8 showed no AR binding. The ethyl 3-amino-1-acyl-1H-pyrazole-4-
carboxylate 7 bound only to A3AR with a Ki = 18.3 μΜ. Compound 6 is an urea derivative with a weak 
affinity against A3AR (Ki = 30.6 μΜ).  
 
Novelty of the tested ligands 
The chemical novelty of the compounds was assessed based on their two-dimensional similarity to any 
known compound tested for binding to ARs. 17,18,19,20,21,22,23,24,25,28 Thus, we calculated the pairwise 
Tanimoto similarity, with extended chemical fingerprints for four atoms (ECFP4), for each of the 
compounds 1-27 to the thousands of known AR ligands in the ChEMBL22 93,94 database using the 
Schrödinger Canvas program (radial fingerprints). 92 For each of the ligands 1-27, the highest Tc value 
compared to all previously characterized AR ligands is presented in Table 1. A Tc value close to zero 
suggests no chemical similarity between a pair of molecules, whereas a value equal to one represents 
two identical molecules. Novel chemotypes for the ARs were discovered as reflected by their low 
Tanimoto coefficients (Tc = 0.14-0.33).  
The 2-amino-3-aroylthiophenes 100,101,102,103,75,104,105 and the 2-amino-3-aroyl-5,6,7,8-tetrahydro-
4H-cyclohepta[b]thiophenes, 105 which are respectively A1AR allosteric agonists and A1AR 
antagonists, 105,106 were found to be most similar with the A2A/A3AR ligands of class A (Tc = 0.22-
0.34). Compounds of class B and D differ the most from previously known structures with Tc < 0.17 
(see Tables 1, S4, and Supporting Information for the structures of the most similar compounds found 
for classes B-E). The results indicate that many compounds which are identified in the present study 
have not experimentally confirmed as binders to the relevant AR subtypes until now.   
In two recent excellent studies, a detailed analysis of PAINS (pan-assay interference compounds) 
alerts 107 in compound libraries was performed. 108,109  From the analysis, it was concluded that the 
blind use of PAINS filters to detect compounds with possible PAINS liabilities should be handled with 
caution, since there is a trend to exclude a priori any potentially reactive compound from further 
consideration. In one of these studies 109 more than 14400 extensively tested compounds containing 
PAINS substructures were detected, and their hit rates were determined. After examining hundreds of 
assays, the hit frequency for PAINS was low, with values of two to five hits for PAINS, and many 
consistently inactive compounds were identified. Future investigations and certain well designed 
computational tools will be highly encouraged to translate the findings of rigorous large-scale data 
analysis into practical guidelines with utility for medicinal chemistry. In these studies, 2-
aminothiophenes were tested in about 650 assays and never produced a hit for PAINS. 109 
Additionally, while in the original study, 2-amino-3-carbonylthiophenes 107 were suspected to be 
PAINS, extensive SAR studies showed that these compounds are promising allosteric A1AR 
modulators. 103,75 Class A compounds  1, 9-13 of the present study included a 2-aminothiophene 
scaffold.  Compounds 5 and 20-25 included the carbonyloxycarboximidamide moiety which is not 
uncommon  structural feature in medicinal chemistry projects. 110 We tested the studied compounds, 
encoded in smiles format, and none of the compounds was identified as PAINS. 111 Additionally, the 
model used to fit the binding data and determine Ki values of all compounds 1-27 confirms competitive 
interaction with the receptor and not a PAINS behavior. 99 Representative plots for compounds are 
shown in Figure 8. The results here show clearly specific and A3-selective binding for a number of 
compounds. The fact that compound 25 and several other compounds show only A3AR binding should 
serve as a valid proof of specific binding rather than random nonspecific interaction.  Screening 
against other GPCRs would not provide a better control than the adenosine receptor subfamily for a 
possible PAINS behavior of the tested compounds.  
 
Computational investigation of ligand-AR complexes 
 
Common structural features in the tested compounds of the different classes A-E and in the receptor 
site among the different AR subtypes gave rise to similar contacts with residues of the binding area. 
Indeed, tested the 27 molecules resulted in similar, stable docking poses with a plausible profile as 
regarding the polar and lipophilic contacts inside the orthosteric binding area of A1, A2A, A3 and 
A2BARs (see for examples docking poses in Figures 1-7 and Figures S8-S14). Ιt has been described 
how difficult it might be to select a proper binding conformation by taking into account only the 
docking score or the presence/absence of specific ligand receptor contacts. 40 An elaborate docking 
protocol was published which enabled a ligand-guided receptor optimization for the generation of 
conformational models for AR subtypes that effectively explain binding modes and subtype selectivity 
for a diverse set of known AR antagonists. 70  
The docking poses of the 27 ligands depicted in Table 1 in complex with A1, A2A, A2B, and 
A3ARs were inserted into a hydrated POPE lipid bilayer and ΜD simulations were performed on these 
systems. POPE membranes were preferred for the MD simulations over DMPC or POPC membranes 
after running MD simulations for 70 ns of the ZM241385-A2A complex in the different hydrated lipid 
bilayers and measuring ligand displacement, RMSDlig, from its crystallographic coordinates. The 
smallest RMSDlig was measured with POPE, ensuring that MD simulations described well the stability 
of the ligand inside the orthosteric binding area (see Figures S4, S5). To establish that the comparison 
was meaningful, the equilibration of the membranes was also tested. To this end, the average area per 
lipid headgroup 81 was measured in the end of the simulation trajectory of each lipid and compared 
with experimental results. The calculated values approached the experimental ones for pure lipid 
bilayers only in the case of POPE (see Figure S6 and Table S2).   
Changes in vdW interactions due to variations of the structure of the ligand structure and of the 
orthosteric binding site (see Figures 1-3) may result in significant changes of hydrogen bonding and 
the overall strength of the binding interactions. Firstly, the MD simulations of the complexes showed 
whether the ligand remained or escaped from the orthosteric binding area. To quantify this, the RMSD 
of the ligand was measured in respect to its docking pose coordinates (see RMSDlig. values in Table 
S3). For complexes where the ligand escapes from the orthosteric binding area, abolishing the 
combination of stabilizing H-bonding and van der Waals interactions, the RMSDlig. values were in 
most of the cases ≥ 4 Ǻ. In those cases where the ligand retained a binding orientation similar to the 
starting docking pose the RMSDlig. values were < 3 Ǻ. It was observed that the former complexes 
correspond to the inactive compounds (Ki > 50 μΜ; see in Table 1) and the latter complexes to 
compounds with a statistically significant experimental binding affinity (Ki ≤ 30 μΜ; see in Table 1). 
We also selected a set of three ligands each being selective against A1AR (coll6), A2AAR (ZM241385) 
and A3AR (jaco_psb11) found in ref. 70. After docking using Gold against these AR subtypes, it was 
found that these compounds also docked well inside the binding area of every AR. The MD 
simulations resulted in a binding orientation similar to the docking pose, only for the AR to which the 
ligand is selective (RMSDlig < 1.5 Å) while in any other case the ligand escaped from the binding area 
(RMSDlig ≥ 4 Å) (see Table S3 and Figures S11-S13). Similarly, compounds ZINC23192718, 
ZINC61843566, and ZINC18155583, which are decoys for A2AAR, produced plausible docking poses 
but during the short MD simulation the ligands escaped from the A2AAR binding area. However, when 
bara_4p or veld_7 in ref. 70 were tested for their binding to A1, A2A and A3 it was found that they 
docked well inside the binding area of the different ARs and that binding orientation of the starting 
docking pose was retained during the MD simulations for all the complexes despite the fact that 
bara_4p was A3 selective and veld_7 was A1 selective (Figure S14 and Table S3). 
As illustrated above, if a ligand is observed to stay bound inside the binding site through MD 
simulations, it still may not be potent because its interactions still are not sufficiently favorable. A 
ligand which escapes from the binding area devoids of biological potency. A potent ligand always 
adopts a stable binding orientation. This exact behavior was observed during the MD simulations of 
the particular set of ligands used in this work. The results of the procedure followed in this work which 
is based on RMSDlig were consistent with binding behavior of the compounds 1-27. This procedure is 
not suggested as generally applicable to predict or explain potency to other systems. The in silico 
quantitative assessment of the experimental binding affinities needs the application of computational 
free energy methods. It is known that approximate free energy methods like MM-PBSA can provide 
good accuracy regarding the correlation between calculated ΔGbind and experimental pΚi values for Κi's 
covering a range of 103 corresponding to a ΔΔGbind scale equal to 4-5 kcal mol-1. 112, 113, 36, 31 In the 
present work, a Κi of 50 μΜ corresponds to an almost inactive compound compared to an active one 
having for example a Κi = 5 μΜ . Such  two compounds differ in ΔGbind by 1.5 kcal mol-1, which is 
well below the accuracy of the MM-PBSA method. In order to explain smaller differences in affinity 
(as for example between compounds 24 and 25), more accurate free energy methods are needed. 114 
Our group has previously applied such methods for this narrow range of binding free energies with 
success 115 116 but this approach is beyond the aim of the present work. 
Secondly, the MD simulations were performed to investigate the binding interactions with A1, 
A2A, and A3ARs for compounds exhibiting affinity. Important changes and SAR results for the most 
significant molecules among 1-27, included in classes A, B and D, are discussed.  
Class A: Compounds 1, 12 and 13 contain one bulky lipophilic CONH-N=CH-Ar group and one 
phenyl group respectively linked at 3- and 5-positions of the 2-aminothiophene ring. Similarly, 
ZM241385 contains one NH(CH2)2Ph(OH) fragment and one 2-furyl group respectively linked to 5- 
and 2-positions respectively of a bicyclic 7-aminotriazolotriazine. The docking calculations and 100 ns 
MD simulations showed that 1, 12 and 13 are stabilized inside the binding pocket of A2AAR with 
similar orientation to ZM241385 (Figures 1a,b and S1) resulting in good affinity against A2AAR (Ki = 
2.67, 3.93 and 4.59 μΜ respectively). The 2-amino group of the thiophene ring is hydrogen-bonded to 
the side chain carbonyl of N(6.55) and to the carboxylate group of E(5.30) in EL2 (see panel b in 
Figure 1 for compound 13). The thiophene ring participates in an aromatic π-π stacking interaction 
with the conserved F(5.29) (EL2) and forms important hydrophobic contacts with I(7.39) (Figure 1a) 
while sulfur atom forms H-bonds with the side chain amide group of N(6.55) (Figure 1b). The CONH-
N=CH-Ar moiety is oriented towards the solvent-exposed part of the binding cavity 15 (EL2 and EL3) 
or at the extracellular end of TM2, between TM1 and TM7 and forms hydrophobic interactions with 
L(7.32) and M(7.35) (Figure 1a). 15,16 This is a similar orientation of the (CH2)2Ph(OH) fragment 
found in the two X-ray structures of A2A-ZM241385 (see Figure 1b and Figures S1-S3). 
15,16 Thus in 
the extracellular end of the receptor, a tremendous flexibility of the ligand is observed compared to 
that of the TM domain. The 5-phenyl group is positioned deeply inside the ligand-binding cavity 
towards TM5 and TM7, engaging in hydrophobic interactions with V(3.32), L(3.33), L(6.51), H(6.52), 
and W(6.48) (Figure 1a,b). In ZM241385, a furyl group forms hydrophobic interactions with these 
residues and is also hydrogen bonding to the side chain amido group of N(6.55); this ring has been 
implicated in both antagonist and agonist binding, as revealed by mutagenesis experiments. 117,118 
The other members of this class, compounds 9-11, lack affinity due to the absence of important 
attractive interactions or exert repulsive forces inside the binding area. Thus, in 9, the 5-phenyl group 
is missing and according to the calculations, the ligand cannot form additional attractive van der Waals 
interactions with residues V(3.32), L(3.33), L(6.51), and H(6.52) positioned deeper in the orthosteric 
binding area compared to compounds 1, 12 and 13. The docking calculations suggested that in 10 and 
11 the condensed cyclopentane or cyclohexane ring exerts steric repulsion to the phenyl group of 
F(5.29) resulting in the abolishment of the critical H-bonding interactions with N(6.55), which was 
confirmed by the MD trajectories before even reaching 10 ns (Figure 4a).  
The docking calculations showed that compounds 1, 9-13 bind inside A1AR with similar 
interaction patterns, but the MD simulation trajectories revealed that the binding poses of 1, 9-12 were 
not stable before reaching 10 ns (Figure 4a). The 100 ns MD simulation revealed a stable binding 
orientation for 13 inside A1AR. Indeed, with the exception of 13 (Ki = 15.2 μΜ) (Figure 2a,b), none of 
the other ligands in this class (1 and 9-12) exhibited affinity against A1AR. If we compare the residues 
in the orthosteric binding area of the ARs, the A1 subtype has the highest homology to A2A with only 
four side chain substitutions on the periphery of the binding pocket. The binding area similarity 
between A1 and A2AARs is 80% while A3 and A2AAR showed 53.33% sequence similarity in the 
binding area (Figure S7). However, the shape of the binding area differs from A2AAR according to the 
recently published X-ray structure of A1AR in complex with the covalently bound antagonist DU172. 
32 It was shown that the A2AR binding pocket is elongated and narrow compared to the very wide and 
open cavity of the A1AR due to the movements of TM1,2,3 and 7, along with EL3. The A2AR pocket 
is narrower since M(7.35) acts as a gatekeeper (see Figure 1a) preventing entry and binding of bulky 
substituents. There is a common region covered by ZM241385 inside A2AAR and DU172 inside 
A1AR, despite their different orientation and depth inside the cavity, and different the shapes and 
volumes of the binding area. The key interactions anchoring ligands ZM241385 and DU172 with their 
respective receptor subtype are preserved. These include a π-π stacking interaction with F(5.29) and a 
bidentate hydrogen bond with N(6.55) formed by different groups linked with the xanthine ring of 
DU172 and the triazolotriazine ring of ZM241385. It was suggested 32 that the binding area of A1AR 
includes the orthosteric and a secondary allosteric binding pocket - the latter not being present in 
A2AAR. When less bulky orthosteric antagonists than DU172, such as DPCPX, are docked into the 
A1AR, a significant part of the binding site is left un-accommodated. This is shown in Figures 1a and 
2a for compound 13 occupying the orthosteric binding area inside A2A and A1ARs with the CONH-
N=CH-Ar moiety orienting towards the solvent-exposed part of the open binding cavity. 15 Compared 
to A2AAR complex, 13 inside the A1AR was positioned closer to TM5 and TM6. This may be the 
result of the more polar environment at the extracellular opening of the A1AR pocket compared to 
A2AAR. The more polar environment is attributed to the presence of T(7.35) instead of M and the 
mutations L(5.28)E and L(7.32)S, combined with a slight shift in the conformation of E(5.30) (Figure 
2a,b). This polar environment may limit the presence of bulky lipophilic groups in the area between 
EL2 and TM7, disfavoring a stable orientation where the hydrogen bonding interactions with N(6.55) 
and E(5.30) of the relevant ligands take place. Thus, among compounds 1, 12, and 13, only the third, 
possessing an Ar = Ph in CONH-N=CH-Ar moiety, binds to A1AR (Figures 1, 2) in contrast to 1 and 
12 where the phenyl ring is substituted with one or three methoxy groups respectively (see Figure 5 for 
1). Regarding compounds 9, 10 and 11, the MD simulations suggested that no stable complex is 
formed at the orthosteric binding region of A1AR (see Figure 4b for ligand 11), similarly to the case 
with A2AAR described above.   
All molecules 1, 9-13 exert moderate weak to low micromolar affinity against A3AR with Ki 
values of 37.1, 16.5, 14.8, 5.77, 5.16 and 3.10 μΜ respectively. At the 5.30 position of A3AR subtype 
unlike the A2AR, the glutamic acid is substituted with valine.  As a consequence, ligands with lipophilic 
groups can be accommodated more effectively in this region of the binding area compared to the other 
AR subtypes (Figure 3a,b). These bulky groups are tolerated since V(5.30) can produce suitable 
rotamers which enable the reduction of van der Waals repulsions. 15,70 Similarly, the replacements 
T(6.58)I, M(7.35)L allow the presence of bulky groups to protrude towards the extracellular opening 
of the pocket (see Figure 3b). It was shown 70 that when an optimized conformation of V(5.30) side 
chain was applied in control docking calculations against A3AR, the enrichment of known A3AR 
ligands with bulky amine substitutions or neighboring lipophilic fragments among a database of 
decoys was substantially increased. Hence, we adopted this rotamer and obtained reliable binding 
poses in which the CONH(CH2)2Ar moiety in 9-11 and the CONH-N=CH-Ar moiety in 12 and 13 
were oriented towards the solvent-exposed part of the open binding cavity (Figures 3a,b, 4c, 5c). The 
molecules shifted slightly towards TM5 and TM6, compared to their binding orientations against A2A 
and A1ARs, to fit better their bulky lipophilic groups close to V(5.30). The 100 ns MD simulations 
showed that the binding orientation of compound 13 was stabilized through the hydrogen bonding of 
the 2-amido group of the ligand with the side chain carbonyl group of N(6.55) and equally with the 
carbonyl group of F(5.43) or S(6.53) of the TM helices; in this last case, the NHCO group of the ligand 
interacted with N(6.55) (see Figure 3a,b). Furthermore, H-bonding interactions between N(6.55) amide 
side chains and the sulfur atom of the thiophene ring of the ligand were observed in the trajectory. 
Compounds 9-11 were less potent compared to 1, 12 and 13. Compound 9 lacks a 5-phenyl group 
which may allow attractive interactions with residues L(6.51) and H(6.52) deeply inside the binding 
area; the 5-aryl group seems to be favorable for binding to A1 and A2AARs according to the results of 
the present study. As discussed previously for 10 and 11, the condensed cyclopentane and cyclohexane 
ring prevents the ligand from adopting an optimal orientation for H-bonding interactions with N(6.55). 
Nevertheless, these molecules fit inside the more lipophilic binding area of A3AR, according to the 
MD simulations for 100 ns, in contrast to A1 and A2AARs (Figure 4). Between 1, 12 and 13 the most 
potent ligand against A3AR is 1, in agreement with the more favorable interactions in the region 
around V(5.30) due to presence of a more lipophilic group (Figure 3a,b, 5c). Compound 13 was found 
to bind to A1, A2A and A3AR. 
Class B: Similarly to what was discussed for 13, the docking calculations and MD simulations 
against A2A and A1ARs showed that the bulky lipophilic groups of 16, 17 are likewise oriented to the 
area of EL2 (Figure 6, Figure S8). The measured affinity of 16, 17 measured against A2AAR was Ki = 
1.18, 1.09 μΜ and against A1AR was 4.69 and 7.29 μΜ, respectively. Similarly to the 2-amino group 
binding to N(6.55) in class A molecules, the 100 ns MD simulations showed that the 2-amido group of 
the thiophene ring can be hydrogen-bonded to the amido group of N(6.55) in A2A and A1AR and/or 
with the carboxylate group of E(5.30), while sulfur of the thiophene ring may also form a H-bond with 
the amido group of N(6.55). The 100 ns MD simulations showed that the van der Waals interactions of 
16 and 17 inside the binding cavity of A2AAR are similar to those described above for the A2A in 
complex with 13 of class A molecules. The 100 ns MD simulation of the Α1AR-17 complex showed 
that the ligand moved slightly higher in the orthosteric binding site and the 5-aryl-thiophene ring was 
inclined so that the 3-NHCOR substituent can be directed between TM7 and TM2, compared to A2A-
AR-17 complex. The 2-amido carbonyl group of the ligand can be hydrogen-bonded to E(5.30). This 
movement can be realized due to the broader area between TM1, TM2,TM5 and TM6 as it was shown 
recently in the X-ray structure of the A1AR-DU172 complex (PDB ID 5UEN 
32). The ligand is 
embraced by Y(7.36), H(7.43), L(7.32), L(6.51), F(5.29), L(5.28) and I(2.66), and the thiophene ring 
induces an aromatic π-π stacking interaction with F(5.29) (Figures 6, S7). This orientation cannot be 
adopted by 16, possibly because of its longer 3-NHCOR group. The 100 ns MD simulations showed 
that in this case the entire molecule shifts slightly towards TM2. The 2-amido carbonyl group of the 
ligand can be hydrogen-bonded to the side chain of N(6.55), while the amino part of that same group 
to the carboxylate of E(5.30). The NH part of the 3-NHCOR moiety can be also hydrogen-bonded to 
E(5.30) side chain. The replacement of E(5.30) with V in A3AR orthosteric cavity retained the binding 
of compounds 16 and 17 as shown by their respective Ki values of 1.65 and 0.918 μΜ, with the latter 
value corresponding to one of the lowest affinities against A3AR. The 100 ns MD simulations showed 
that the molecules shifted slightly towards TM5 and TM6, compared to their binding orientations 
against A2A and A1ARs, to fit better their bulky lipophilic groups close to V(5.30) (Figure 6). The 
ligands were stabilized through the formation of a bidentate hydrogen bond between their 2-amido 
group and the amide side chain of N(6.55).  
In compound 18, the thiophene ring possesses a NHCOCH2SPh(CF3)2 moiety. The MD 
simulations predicted that 18 cannot be stabilized inside the orthosteric binding area of A2A and 
A1ARs, either when NHCOR group is oriented towards the solvent exposed area - because of the 
presence of two polar CF3 groups in the area close to E(5.30) - or when NHCOR group is oriented 
towards TM2 - since the group is bulky and the molecule should anchor the p-Cl-phenyl group in the 
receptor. In contrast, an orientation of NHCOCH2SPh(CF3)2 moiety pointing to the solvent-exposed 
area was well accommodated by the replacement of E(5.30) with V and the 100 ns MD simulation 
trajectory revealed a stable complex. Indeed compound 18 was the only class B antagonist with 
affinity solely against A3AR (Ki = 1.55 μΜ). Compared to 16-18, compounds 15, 26 and 27 lack the 5-
phenyl substituent, which led to affinity only against A1 and A3AR for 15, 26 or A1 for 27 (Ki = 7.48, 
5.39 μΜ for 15, Ki = 7.33, 27.4 μΜ for 26 and Ki = 18 μΜ for 27). The results showed that a 
substituent buried deep between TM3, TM5, TM6 and TM7, and making contacts with V(3.32), 
L(3.33), L(6.51), and H(6.52) is important for affinity against A2AR, similarly to the 2-furyl substituent 
of ZM241385 as has been demonstrated from antagonist and agonist binding and mutagenesis 
experiments. 117,118 Compound 14 which lacks the bulky 3-acylamino substituent of the 3-thiophene 
ring (compare to structures of 16 and 17) has a moderate affinity against A2A and A3ARs and no 
affinity against A1AR. 
Class D: These molecules have a propensity to exhibit selectivity for A3AR. The docking poses 
and the 100 ns MD simulations showed that the bulky phenyl-isoxazole biaryl group can be positioned 
close to V(5.30) of the A3AR orthosteric binding area. In this binding position the phenyl group of the 
3-phenyl-isoxazole can interact -through attractive van der Waals forces- with the iPr side chain of 
Val, and the isoxazole ring can engage in an aromatic π-π stacking interaction with the phenyl group of 
F(5.29) (Figures 7, S15, S16). The monoaryl group is oriented deeper into the receptor favouring 
interactions with L(6.51). The binding orientation is stabilized due to the H-bonding interactions 
between: a) the amino group of the carbonyloxycarboximidamide molecular segment and the amide 
sidechain of N(6.55) along with the backbone carbonyl of L(6.51). b) the nitrogen and oxygen atoms 
of isoxazole and the NH groups of F(5.29) and V(5.30), respectively. c) the thiazole monoaryl group N 
or S and N(6.55) sidechain. Compounds 22, 24 and 25 were selective against A3AR with Ki values 
4.49, 4.16 and 0.899 μΜ respectively. Compound 21 binds also to A1AR and 23 and 5 bind also to 
A2AAR. Compound 21 shows a Ki = 6.90 μΜ for A1AR and 4.13 μΜ for A3AR. Compound 23 shows 
Ki = 30 μΜ for A2AAR and 5.15 μΜ for A3AR. Compound 5 shows a Ki = 21.8 μΜ for A2AAR and 
9.45 μΜ for A3AR. When the residue (5.30) is changed from valine to the negative charged glutamic 
acid in A2AAR, the phenyl group of 3-phenyl-isoxazole can be oriented towards the TM2 through 
rotation around the biaryl-carbonyloxy bond to avoid any unfavourable interactions with the E(5.30) 
carboxylate group. Representative MD simulations of 5 showed that this movement enabled the ligand 
to be stabilized inside the A2AAR orthosteric binding area between TM5, TM6 and TM2 with the 
monoaryl group being in spatial vicinity to TM5 and the phenyl-isoxazolyl group close to TM2. This 
region is wider, and thus the ligand cannot bind tightly inside A1AR (Figure 7). Compared to 5, 
compound 25 possesses two chlorine atoms attached to the phenyl ring and this resulted in the 
selectivity of 25 against A3AR. The MD simulations showed that the dichlorophenyl ring favors 
increased van der Waals interactions with F(5.29) and V(5.30) which enable the ligand to form 
stronger H-bonding interactions with side chain of N(6.55) and the backbone carbonyl of L(6.51) (see 
the ligand-protein diagrams in Figures S15, S16). In 3, which lacks affinity for all ARs, the monoaryl 
and biaryl groups are connected to the carbonyloxycarboximidamide fragment in a transposed manner, 
i.e. the biaryl group is connected to the carboximidamide carbon and the monoraryl moiety to the 
carbonyl group. The biaryl group is bulky and cannot be fitted deep into the receptor, towards L(6.51) 
and W(6.48). This kind of transposition in N-acylhydrazones 119 has previously shown to affect 
seriously the affinity for A2AAR. In the aminomethylidenehydrazine-1-carboxamide 4, some proximal 
polar groups are simultaneously present, i.e. the methylidenehydrazide group, the urea group and 
pyridine. All of these groups provide H-bond donor atoms which are in spatial proximity, thus 
interacting at the same space, prohibiting the stabilizing binding to N(6.55) or/and E(5.30). Indeed, the 
molecule was not stable inside the binding area, according to the MD simulations. 
MD simulations were also performed for compounds of Classes C and E (see Figure S9; relevant 
information for these compounds can be found in the Supporting Information). The MD simulations 
for some A2B-ligand complexes showed that the ligand retained a binding orientation similar to the 
starting docking pose after 100 ns (see Figure S10). Since all compounds were inactive against A2BAR, 
according to an adenylyl cyclase activity assay, 120 the simulation results were deemed ambiguous and 
no additional simulations were realized. Most likely, a different experimental structure of the binding 
area exists that deviates from that predicted by homology modeling.  
 
Conclusions 
 
Pharmaceutical companies and academic research laboratories are involved in intense efforts to 
identify antagonists with selectivity for each adenosine receptor (AR) subtype as potential clinical 
candidates for "soft" treatment of different diseases. A2AR antagonists can be useful for treating cancer, 
central nervous system (CNS) disorders; A1AR antagonists can provide kidney-protective agents, anti-
asthmatic and CNS agents; A3AR antagonists are promising for therapeutic applications in asthma, 
glaucoma and A2BAR antagonists for diabetes, asthma and chronic obstructive pulmonary disease. 
The reported crystal structures of A2AAR in complex with agonists or antagonists 
15,16,21,121,122,123 
and of A1AR with an antagonist, 
32,33 along with other advances attributed to the progress of GPCR 
crystallography 124 have made structure-based approaches an attractive strategy for drug design against 
adenosine receptors which are pharmaceutically important targets. The A2AAR is one of the best 
studied receptors of all class A GPCRs. Additionally, among the 688 known GPCRs, class A is the 7th 
more intensely investigated. The application of virtual screening and medicinal chemistry studies for a 
few decades now has resulted in a high number of bioactive compounds (~ 11000) against A2AAR as 
was retrieved from ChEMBL20. In the present study, we performed virtual screening of a small 
Maybridge library of 14400 compounds for A2AAR, using its crystallographic structure in complex 
with the antagonist ZM241385, through a combination of structure-based and ligand-based procedures. 
After docking, the ligand poses were re-scored by applying CHARMM energy minimization and 
consideration of desolvation energy electrostatics using the Poisson-Boltzmann equation. Out of the 
eight selected and tested compounds, three showed micromolar affinity for the A2A and A3ARs and 
two were low micromolar binders only to the A3AR receptor. Thus, although initially targeting the 
A2AR, the project resulted in the following percent of successful antagonist hits: 25% for A2A and 63% 
for A3AR. In a second step, based on the structure of mainly two promising active hits, possessing a 2-
amino-thiophene-3-carboxamide and a carbonyloxycarboximidamide chemotype respectively, 19 more 
compounds were selected by similarity for testing. For this second series of seventeen compounds, 
sixteen were found to bind to the ARs family. Eight of those revealed A3-selective affinity with Ki 
values in the micromolar to low micromolar regime.  
The 27 tested molecules resulted in similar docking poses against A1, A2A, A2B or A3ARs. The 
MD simulations of numerous complexes using Desmond/OLPS2005 and Amber/ff14sb provided the 
basic features of the binding interactions with A1, A2A, and A3ARs for compounds exhibiting affinity. 
Using the docking poses of the antagonists as starting structures, the MD simulations suggested 
features of their binding inside the orthosteric binding area of A2A, A1 and A3ARs. The complexes with 
A2A and A1ARs were stabilized through H-bonding interactions between an amino or amido group of 
the ligand and N(6.55) of the AR. E(5.30) can be involved also in H-bonding interactions with the 
bound ligand. A2AAR antagonists include a lipophilic bulky substituent which was oriented towards 
the extracellular area, close to EL2 and TM7, and a smaller lipophilic group which was fitted deep in 
the binding region, close to L(6.51) and H(6.52). Similar interactions were described in the X-ray 
structures between antagonists and A2AAR. 
15,16,21 Interestingly, for the A1AR antagonists the ligand 
covers a larger space between TM5/TM6 and TM1/TM2, as shown in the recent X-ray structure 
between an antagonist and A1AR. 
32 Many of the ligands studied in this report may be considered to be 
more lipophilic than ZM241385 (which has a triazolotriazine central ring) and it was found that most 
of them (1, 2, 5-7, 9-18 and 20-25) interact with A3AR. We suggest that selectivity against A3AR is 
boosted by increasing the size and lipophilicity of a suitable substituent reflecting a better fit with 
V(5.30). Compounds 6, 7, 9-11, 18, 20, and 22-25 acted as selective antagonists against A3AR. These 
findings are in line with the previously published results on highly selective A3AR agonists and 
antagonists with a bulky group in a compatible position, e.g. the introduction of a 3-iodo-benzyl group 
in N6 position in 2-Chloro-N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (Cl-IB-MECA) 
increases the affinity of this adenosine derivative for A3AR.
118,119 
Relatively novel chemotypes  of ARs antagonists were identified. Two classes of compounds were 
found with low Tc values (< 0.17): a) The 3-acylamino-5-aryl-thiophene-2-carboxamides (class B) 
including the new substitution pattern (2-CONH2 and 3-NHCOR) of the thiophene ring, which -
compared to 2-NH2 and 3-CONHR' substitution pattern- enhanced the affinity for A1 and A3AR. b) 
The carbonyloxycarboximidamide derivatives (class D), which favour A3AR affinity. The A3AR 
subtype is the most divergent from all other ARs, with 10 out of 20 side chains in the binding pocket 
being unique. The micromolar affinity, selective A3AR antagonists found here provide novel, 
relatively simple chemotypes which may contribute to the treatment of the A3AR-related human 
pathologies. 
We consider these findings to be an important contribution to the field of structure-based drug 
design against ARs and also a valuable example showing that the in silico screening of a small library 
against a receptor family can lead to novel hits when careful scoring of the relative free energy of 
binding is applied. 
 
6 Supporting Information available 
 
Supplementary material includes fourteen figures, details and results from few complementary MD 
simulations and five tables. This material is available free of charge via the Internet at 
http://pubs.acs.org.  
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Transmembrane, TM; Extracellular loop, EL2; POPE, 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; GPCRs, G protein-
coupled receptors; MD, Molecular dynamics; CNS, central nervous system; PD, Parkinson's disease; 
RMSD, root-mean-square deviation; PB, Poisson-Boltzmann; PDB, Protein data bank; OPM, 
Orientations of Proteins in Membranes; PME, particle mesh Ewald method; RESPA, Reversible 
multiple time scale molecular dynamics; ROCS, Rapid Overlay of Chemical Structures; ECFP4, 
extended chemical fingerprints for four atoms; CheMBL, Cheminformatics European Molecular 
Biology Laboratory CCPA, 2-chloro-N6-cyclopentyladenosine; NECA, 5'-N-
ethylcarboxamidoadenosine; HEMADO, 2-hexyn-1-yl-N6-methyladenosine. DPCPX, 
Dipropylcyclopentylxanthine.  
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11 Schemes and Figures captions 
 
Scheme 1. Workflow used for the discovery of new hits.  
 
Figure 1. Predicted binding mode for ligand 13 in the orthosteric site of the A2AAR. (a) Top-view of 
the orthosteric binding site. Sidechains of amino acids important for binding are shown in blue sticks. 
(b) Lateral view of the complex, facing helices TM6 and TM7, with the structure of TM7 partially 
omitted. MD optimization of the docking pose showed that 13 can adopt a binding orientation in which 
the amino group of the thiophene ring is hydrogen-bonded to the carbonyl of amide group of N(6.55) 
and the carboxylate of E(5.30) in EL2. The thiophene ring has an aromatic π-π stacking interaction 
with the conserved F(5.29) (EL2) and forms important hydrophobic contacts with I(7.39), while the 
sulfur atom forms H-bonds with the amide group of N(6.55). In panel (a) side chains of amino acids 
important for binding are displayed in blue sticks. In panel (b) side chains of amino acids important for 
binding are displayed as gray sticks. Binding orientation of the ligand after the MD simulation is 
shown in yellow sticks and sidechains of some amino acids involved in ligand binding are displayed as 
gray sticks while the starting ligand and Ν(6.55)/Ε(5.30) side chain positions are shown in green wires. 
Hydrogen atoms are omitted except for those involved in hydrogen bond interactions, highlighted as 
black dashed lines. MD simulations of 13 in complex with the ARs were performed for 100 ns. 
 
Figure 2. Top view and side view of the predicted binding mode for ligand 13 in the orthosteric site of 
the A1AR. In panel (a) the sidechains of amino acids important for binding are displayed in yellow 
sticks. In panel (b) the sidechains of amino acids important for binding are displayed as gray sticks. 
Binding orientation of the ligand after the MD simulation is shown in yellow sticks and sidechains of 
some amino acids involved in ligand binding are displayed as gray sticks while the starting ligand and 
Ν(6.55)/Ε(5.30) side chain positions are shown in green wires. Hydrogen atoms are omitted except for 
those involved in hydrogen bond interactions, highlighted as black dashed lines. MD simulations of 13 
in complex with the ARs were performed for 100 ns. 
 
Figure 3. Top view and side of the predicted binding mode for ligand 13 in the orthosteric site of the 
A3AR. In panel (a) the sidechains of amino acids important for binding are displayed in pink sticks. In 
panel (b) the sidechains of amino acids important for binding are displayed as gray sticks. Binding 
orientation of the ligand after the MD simulation is shown in yellow sticks and sidechains of some 
amino acids involved in ligand binding are displayed as gray sticks while the starting ligand and 
Ν(6.55)/Ε(5.30) side chain positions are shown in green wires. Hydrogen atoms are omitted except for 
those involved in hydrogen bond interactions, highlighted as black dashed lines. MD simulations of 13 
in complex with the ARs were performed for 100 ns. 
 
Figure 4. The MD simulations of the docking pose of 11 against A2A (panel a), A1AR (panel b) 
showed that the binding orientation is not stable, probably due to the steric crowding induced by the 
cyclohexyl ring. (c) In contrast, MD simulations for 100 ns showed that the binding region of A3AR 
can accommodate the cyclohexyl ring and ligand 11 can adopt a binding orientation in which the 
amino group and sulfur atom of the thiophene ring can form H-bonding interactions with N(6.55). The 
sidechains of some amino acids involved in ligand binding are displayed as gray sticks. Binding 
orientation of the ligand after the MD simulation is shown in yellow sticks and sidechains of some 
amino acids involved in ligand binding are displayed as gray sticks while the starting ligand and 
Ν(6.55)/Ε(5.30) side chain positions are shown in green wires. Hydrogen atoms are omitted except for 
those involved in hydrogen bond interactions, highlighted as black dashed lines.  
 
 Figure 5. (a) MD simulations of the docking pose of 1 against A1AR showed that the binding 
orientation is not stable, probably because binding site is narrower for A1AR. (b) In contrast MD 
simulations for 100 ns showed that the binding region of A2AAR, and (c) of A3AR can accommodate 
the ligand which adopts a binding orientation where the amino group and thiophene sulfur atom can 
form H-bond interactions with N(6.55). Sidechains of the amino acids crucial for ligand binding are 
displayed as gray sticks. Binding orientation of the ligand after the MD simulation is shown in yellow 
sticks and sidechains of some amino acids involved in ligand binding are displayed as gray sticks 
while the starting ligand and Ν(6.55)/Ε(5.30) side chain positions are shown in green wires. Hydrogen 
atoms are omitted except for those involved in hydrogen bond interactions, highlighted as black 
dashed lines.  
 
Figure 6. Predicted binding modes before and after 100 ns MD simulations for ligand 17 in the 
orthosteric binding site of (a) A1, (b) A2A and (c) A3AR, resulting in stable complexes. Compound 17 
can adopt a binding orientation inside A2AAR in which the amido group of thiophene ring is hydrogen-
bonded to N(6.55) and E(5.30), and van der Waals interactions stabilize the ligand inside the binding 
cavity. The replacement of E(5.30) with V in A3AR orthosteric cavity (panel c) retained the binding of 
compound 17, as a result of hydrogen-bonding to N(6.55) and additional favourable van der Waals 
interactions of its bulky lipophilic group in the vicinity of V(5.30). In A1AR, which has a broader 
binding cavity, the 5-aryl-thiophene ring is inclined and the 3-NHCOR substituent is directed towards 
TM2.  Binding orientation of the ligand after the MD simulation is shown in yellow sticks and 
sidechains of some amino acids involved in ligand binding are displayed as gray sticks while the 
starting ligand and Ν(6.55)/Ε(5.30) side chain positions are shown in green wires. Hydrogen atoms are 
omitted except for those involved in hydrogen bond interactions, highlighted as black dashed lines.  
 
Figure 7. (a) Predicted binding of ligand 5 in the orthosteric binding area of the A2AAR using docking 
calculations and MD simulations, with the docking pose being used as a starting structure. The ligand 
was stabilized inside the A2AAR binding area between TM5, TM6 and TM2, with its monoaryl group 
close to TM5 and the phenyl-isoxazolyl substituent close to TM2. (b) This area is wider and the ligand 
cannot bind tightly inside A1AR. (c) Binding of 5 inside A3AR is highly favoured and the ligand 
engaged in many stabilizing interactions. In the depicted binding orientation the phenyl group of the 3-
phenyl-isoxazole interacts through attractive van der Waals forces with the iPr side chain of V(5.30) 
and the isoxazole forms an aromatic π-π stacking interaction with the phenyl group of F(5.29). The 
amino group of the carbonyloxycarboximidamide fragment is H-bonded to the amide side chain of 
N(6.55). Nitrogen and oxygen atoms of the isoxazole ring can be hydrogen-bonded to the NH groups 
of F(5.29) or V(5.30). The thiazolyl group can be hydrogen-bonded to N(6.55). Binding orientation of 
the ligand after the MD simulation is shown in yellow sticks and sidechains of some amino acids 
involved in ligand binding are displayed as gray sticks while the starting ligand and Ν(6.55)/Ε(5.30) 
side chain positions are shown in green wires. Hydrogen atoms are omitted except for those involved 
in hydrogen bond interactions, highlighted as black dashed lines.  
 
Figure 8. Competition binding curves for selected compounds at the A3 adenosine receptor. The 
curves show the result of single representative experiments for compounds 1 (class A), 17 (class B), 
and 25 (class D). The competing radioligand was [3H]HEMADO (1 nM). The Ki values from these 
individual experiments were 3.4 µM (compound 1), 0.96 µM (compound 17), and 0.76 µM (compound 
25). The data were fitted assuming a one-site competition model. 
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13 Tables 
 
Table 1. Binding affinities obtained from radioligand binding assays and chemical structures of the 
eight hits (compounds 1-8) from the docking screen and the 19 compounds (9-27) selected and tested 
based on the structures of 1, 2 and 5 against the A1, A2A, A2B 
a and A3ARs.  
 
Class 
Compound 
number 
Chemical structure Ki (μΜ) b Tc c 
   A1AR A2AAR A3AR  
A 1 
 
>100 
2.67 
(2.26-3.15)e 
3.10 
(2.48-3.88) 
0.22 
A 9 
 
>100 >60 
37.1 
(23.0-60.0)d 
0.32 
A 10 
 
>30 >60 
16.5 
(11.2-24.3) 
0.34 
A 11 
 
>30 >60 
14.8 
(12.3-17.8) 
0.34 
A 
12 
 
 
>100 
3.93 
(2.85-5.42) 
5.77 
(5.34-6.23) 
0.21 
A 13 
 
15.2 
(10.5-22) 
4.59 
(3.18-6.63) 
5.16 
(4.77-5.57) 
0.24 
B 14 
 
>30 
31.7 
(24.9-40.3) 
19.7 
(11.6-33.4) 
0.25 
B 15 
 
7.48 
(5.72-9.78) 
>100 
5.39 
(4.72-6.15) 
0.16 
B 16 
 
1.18 
(1.09-1.28) 
4.69 
(3.98-5.52) 
1.65 
(1.24-2.21) 
0.14 
B 17 
 
1.09 
(1.0-1.17) 
7.29 
(6.86-7.76) 
0.918 
(0.813-1.04) 
0.19 
B 18 
 
>100 >100 
1.55 
(1.25-1.93) 
0.17 
B 26 
 
7.33 
(6.80-7.70) 
>100 
27.4 
(20.1-32.5) 
0.20 
B 27 
 
18.0 
(13.0-21.2) 
>100 >100 0.18 
C 2 
 
≥100 
61.3 
(52.6-71.5) 
16.6 
(11.5-23.9) 
0.17 
C 19 
 
>100 >100 >100 0.20 
D 3 
 
>100 >100 >100 0.13 
D 4 
 
≥100 >100 >100 0.14 
D 5 
 
>100 
21.8 
(18.1-26.2) 
9.45 
(8.75-10.2) 
0.16 
D 20 
 
>100 >100 
30.9 
(20.8-45.8) 
0.16 
D 21 
 
6.91 
(6.36-7.52) 
>100 
4.13 
(3.38-5.04) 
0.15 
  
a All compounds did not exhibit binding evidence to A2BAR. 
b Measured in three independent 
experiments. c Tanimoto similarity coefficient to the closest annotated AR ligand from ChEMBL (see 
Table S4). 
 
 
 
D 22 
 
>60 >60 
4.49 
(4.13-4.88) 
0.16 
D 23 
 
>60 
30 
(26.7-33.8) 
5.15 
(4.51-5.88) 
0.17 
D 24 
 
>30 >60 
4.16 
(3.56-4.87) 
0.16 
D 25 
 
>100 >100 
0.899 
(0.766-1.060) 
0.14 
E 6 
 
>100 >100 
30.6 
(17-55) 
0.21 
E 7 
 
>100 >100 
18.3 
(10.3-32.7) 
0.21 
E 8 
 
>100 ≥100 >100 0.15 
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